Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure

Horng‐Ruey Chua, Ian Baldwin, Michael Bailey, Ashwin Subramaniam, Rinaldo BellomoJournal of Critical Care 2012 · DOI

TL;DR

This study investigates the lifespan of circuits used in continuous renal replacement therapy (CRRT) for patients with combined liver and kidney failure. It reveals that circuit lifespan is surprisingly short and not significantly improved by heparinization, with thrombocytopenia emerging as a key predictor of both longer circuit life and bleeding complications.

What Problem Does This Paper Address?

Critically ill patients with acute liver failure (ALF) or decompensated chronic liver disease (DCLD) often develop acute kidney injury (AKI). This dual organ dysfunction presents a significant challenge, as these patients frequently require renal replacement therapy (RRT). Continuous renal replacement therapy (CRRT) is the preferred mode due to its ability to manage fluid balance and prevent cerebral edema. However, a major hurdle in CRRT is circuit clotting, which can compromise treatment efficacy and lead to blood loss. In patients with liver failure, coagulopathy is common, making anticoagulation for CRRT risky. Consequently, many of these patients receive CRRT without anticoagulation. The problem this paper addresses is the lack of understanding regarding the circuit lifespan (CL) and bleeding risk in this specific, high-risk patient population managed without anticoagulation, and whether standard coagulation parameters can predict these outcomes.

Methods

This was a single-center, retrospective analysis of critically ill adult patients diagnosed with ALF or decompensated chronic liver disease (DCLD) complicated by AKI. Patients admitted to the intensive care unit (ICU) who received CRRT between January 2006 and July 2011 were included. The study analyzed 539 CRRT circuits. Circuit lifespan was defined as the time from initiation to cessation of therapy, patient death, ICU discharge, or liver transplantation. Data on patient demographics, clinical characteristics, laboratory results (including hemoglobin, platelet counts, INR, and APTT), CRRT parameters (including anticoagulation strategy), and bleeding complications were collected. Statistical analysis involved univariate and multivariate linear regression for circuit lifespan and logistic regression for bleeding complications. Kaplan-Meier plots and log-rank tests were used to assess the differential effects of variables on circuit lifespan.

Datasets

The study utilized data from 71 patients, comprising 539 CRRT circuits, collected retrospectively from the ICU admission database of a regional tertiary referral center. No new datasets were introduced.

Key Insights and Ideas

  • Short Circuit Lifespan is the Norm: Contrary to potential expectations that coagulopathy might inherently protect circuits, the study found that CRRT circuits in liver failure patients have a remarkably short lifespan, with a median of only 9 hours.
  • Heparinization Offers Little Benefit: Despite the common practice of attempting anticoagulation, the study found no significant improvement in circuit lifespan when heparinization was used, even with elevated APTT levels. This suggests that standard heparinization strategies are largely ineffective in this population.
  • Thrombocytopenia is a Double-Edged Sword: Perhaps the most striking finding is that thrombocytopenia (low platelet count) is independently associated with both a longer circuit lifespan and an increased risk of bleeding complications. This highlights the complex interplay of hemostasis in liver disease.
  • Beyond Standard Coagulation Tests: Conventional coagulation parameters like INR were not strong predictors of circuit lifespan or bleeding risk, underscoring the limitations of these tests in assessing the complex hemostatic derangements in liver failure.
  • Other Predictors Emerge: Higher baseline APTT and serum bilirubin levels, and the absence of mechanical ventilation, were associated with longer circuit lifespan. Conversely, prolonged vasoactive drug use and higher baseline APTT were linked to increased bleeding complications.

Key Results

  • The overall median circuit lifespan (CL) was 9 (6-16) hours.
  • In patients never anticoagulated for CRRT (n=51), the median CL was 12 (7-24) hours.
  • In patients who subsequently received heparinization (n=20), the median CL was 7 (5-11) hours, showing no significant improvement (P = .231) compared to no anticoagulation.
  • Thrombocytopenia was a significant predictor of longer CL (P < .0001) and bleeding complications (P < .05). Specifically, decreasing platelet counts, especially below 50 × 10⁹/mm³, had an incremental effect on CL.
  • Higher baseline APTT and serum bilirubin were associated with longer CL (P < .05).
  • Prolonged vasoactive drug use (>24 hours) and thrombocytopenia predicted more bleeding complications (P < .05).
  • Of 71 patients, 33 (46.5%) had significant bleeding events.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: This limits the ability to establish causality and may be subject to interpretation bias in assessing reasons for premature circuit termination.
  • Single-Center Study: Findings may not be generalizable to other healthcare systems.
  • Vascular Access: The vast majority of patients used femoral venous access, limiting applicability to other access sites.
  • ALF vs. DCLD Pooling: The study pooled patients with ALF and DCLD, despite potential differences in their thrombogenic milieu.
  • CRRT Modality and Transfusions: The study could not account for the effects of specific CRRT modalities (diffusive vs. convective) or plasma/platelet transfusions on circuit clotting.

Future work suggested includes:

  • Developing improved techniques to assess hemostasis in this unique patient cohort.
  • Investigating alternative strategies to optimize CRRT circuit longevity without compromising patient safety.
  • Exploring the potential of regional citrate anticoagulation, given emerging data on its safety in liver patients.
  • Regularly reviewing the need for anticoagulation in light of progressive decreases in platelet count and bleeding risk.
  • Utilizing thromboelastography for a better assessment of hemostasis during extracorporeal circulation in liver failure.

Summary updated

BibTeX
@article{chua2012circuit,
  author = {Horng‐Ruey Chua and Ian Baldwin and Michael Bailey and Ashwin Subramaniam and Rinaldo Bellomo},
  title = {{Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure}},
  journal = {Journal of Critical Care},
  year = {2012},
  doi = {10.1016/j.jcrc.2012.08.016},
}
Figure